Plain-English translation of NCT05773040 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which uses your own immune cells (T cells) that have been engineered in the laboratory to recognize and fight cancer cells. The treatment is designed for people whose B-cell lymphoma has come back or stopped responding to standard therapies. Researchers want to understand the right dose, safety profile, and how well this medication works.
Many patients with aggressive B-cell lymphomas run out of effective treatment options when their cancer becomes resistant to standard chemotherapy and other drugs. This trial exists to explore whether helping the immune system attack cancer cells in a new way might offer hope to people in this difficult situation.
You likely qualify if…
You likely don't qualify if…
The study has two parts: first, researchers will test different doses of the medication in small groups to find the safest and most effective dose; then, more patients will receive the recommended dose. Before treatment, you will undergo a procedure called leukapheresis, where some of your blood cells are collected and sent to a laboratory to be modified. You will then receive the engineered cells back as an infusion, followed by close monitoring in the hospital and outpatient clinic visits to watch for side effects and signs of cancer improvement.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~33 participants
Started
April 2023
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sattva Neelapu, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.